Neutropenia
📧 Sign up to get email alerts when something new happens for Neutropenia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-07-08EMA Authorised: Zarzio (filgrastim) — Sandoz GmbH
The EMA authorised Zarzio, a filgrastim biosimilar from Sandoz GmbH, for use in hematopoietic stem cell transplantation and cancer indicatio…
-
CLINICAL_TRIALS research · 2025-07-02Clinical Trial Update: Prospective Study Evaluate the Timing of Empirical Treatment for Carbapenem-resistant Bacterials (CROEAT Study) [NA]
A prospective study evaluating the timing of empirical treatment for carbapenem-resistant bacterial infections, conducted by Shanghai Jiao T…
-
EMA withdrawal · 2025-06-04EMA Application withdrawn: Pelgraz Paediatric (pegfilgrastim) — Accord Healthcare S.L.U.
The EMA has withdrawn the application for Pelgraz Paediatric (pegfilgrastim) submitted by Accord Healthcare S.L.U., in the therapeutic areas…
-
CLINICAL_TRIALS research · 2025-05-31Clinical Trial Update: Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
Describes a global Shwachman-Diamond Syndrome patient survey and partnering platform sponsored by the Shwachman-Diamond Syndrome Alliance, I…
-
CLINICAL_TRIALS withdrawal · 2025-05-02Clinical Trial Update: Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant [NA]
This clinical trial update indicates that the study evaluating a donor stem cell boost for patients with low blood cell counts after a donor…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-04-29FDA Approved: RELEUKO — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for RELEUKO (filgrastim) from Amneal Pharmaceuticals LLC. This reflects regulatory action on a suppl…
-
CLINICAL_TRIALS trial_result · 2025-04-20Clinical Trial Update: Study to Compare the Efficacy and Safety of F-627 and GRAN® [Phase 3]
Phase 3 trial comparing F-627 with GRAN® in breast cancer; the study is completed and results have been posted.
-
FDA approval · 2025-04-18FDA Approved: NEUPOGEN — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for NEUPOGEN (filgrastim) by Amgen, Inc.
-
CLINICAL_TRIALS research · 2025-04-10Clinical Trial Update: Breath Analysis for the Detection of Invasive Fungal Infections
This clinical trial update describes a breath analysis approach being studied to detect invasive fungal infections in patients with leukemia…
-
CLINICAL_TRIALS trial_result · 2025-04-09Clinical Trial Update: Early Termination of Empirical Antibiotics in Febrile Neutropenia in Children With Cancer [NA]
This clinical trial evaluating early cessation of empiric antibiotics in pediatric cancer patients with febrile neutropenia was completed.
-
CLINICAL_TRIALS research · 2025-04-08Clinical Trial Update: The Prevalence and Impacts of Nudix Hydrolase 15 (NUDT15) Gene Variants in Taiwanese Inflammatory Bowel Disease
A recruiting study at National Taiwan University Hospital is examining how NUDT15 gene variants influence inflammatory bowel disease and neu…
-
FDA approval · 2025-03-26FDA Approved: STIMUFEND — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for STIMUFEND (PEGFLILGRASTIM-FPGK) from Fresenius Kabi USA, LLC, expanding/confirming labeling to s…
-
CLINICAL_TRIALS research · 2025-03-21Clinical Trial Update: UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia [Phase 1]
Phase 1 clinical trial evaluating UCMSC-Exo (umbilical cord mesenchymal stem cell-derived exosomes) to address chemotherapy-induced myelosup…
-
CLINICAL_TRIALS withdrawal · 2024-12-30Clinical Trial Update: Remote Monitoring of Patients at Risk of Sepsis [NA]
A trial investigating remote monitoring of patients at risk of sepsis, including those with neutropenia and cancer, has been withdrawn.
-
FDA approval · 2024-10-22FDA Approved: ZARXIO — Supplemental Application (Sandoz Inc.)
FDA approved a supplemental application for Zarxio (filgrastim-sndz) from Sandoz, expanding the biosimilar's approved indications.
-
EMA approval · 2024-08-30EMA Authorised: Ratiograstim (filgrastim) — Ratiopharm GmbH
EMA authorised Ratiograstim (filgrastim) by Ratiopharm GmbH for cancer and hematopoietic stem cell transplantation to reduce chemotherapy-in…
-
CLINICAL_TRIALS trial_result · 2024-08-16Clinical Trial Update: Biosimilarity Study of Subcutaneous Pegfilgrastim in Healthy Volunteers [Phase 1]
Phase 1 biosimilarity study evaluating subcutaneous pegfilgrastim in healthy volunteers to assess pharmacokinetic/pharmacodynamic similarity…
-
CLINICAL_TRIALS trial_result · 2024-08-12Clinical Trial Update: Antibiotics Management of Septic Neutropenic Patients in the Intensive Care Unit
Clinical trial update indicating that the study on antibiotics management for septic neutropenic patients in the Intensive Care Unit has com…
-
FDA approval · 2024-08-09FDA Approved: ZARXIO — Supplemental Application (Sandoz Inc.)
FDA approved a supplemental application for Zarxio (filgrastim-sndz) submitted by Sandoz Inc. Zarxio is a biosimilar to filgrastim used to m…
-
CLINICAL_TRIALS research · 2024-06-04Clinical Trial Update: Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients [NA]
A clinical trial comparing ceftolozane/tazobactam with piperacillin/tazobactam for bacteremia in hematologic malignancy patients with neutro…
-
CLINICAL_TRIALS research · 2024-05-21Clinical Trial Update: A Comparator Study of a Tasso Device Blood Sample to Traditional Venous Blood Sample for CBC
A clinical trial update describes a comparator study evaluating the Tasso device as an alternative to traditional venous blood sampling for …
-
CLINICAL_TRIALS trial_result · 2024-03-19Clinical Trial Update: Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer [Phase 3]
Phase 3 trial assessing reduced-dose pegfilgrastim as support for chemotherapy in breast cancer.
-
CLINICAL_TRIALS trial_result · 2024-02-23Clinical Trial Update: Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy [Phase 1]
Phase 1 trial of F-627 in women with breast cancer receiving myelotoxic chemotherapy has completed with results posted.
-
FDA approval · 2024-01-19FDA Approved: ZARXIO — Supplemental Application (Sandoz Inc.)
FDA approved a supplemental application for Zarxio (filgrastim-sndz) filed by Sandoz Inc., resulting in labeling changes under the supplemen…
-
CLINICAL_TRIALS trial_result · 2023-12-27Clinical Trial Update: Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial updating the use of colony-stimulating factors to relieve neutropenia in patients with recurrent non-Hodgkin's lymphoma.